|
Real-time
Euronext Paris
08:13:47 19/10/2026 pm IST
|
5-day change | 1st Jan Change | ||
| 2.170 EUR | +0.93% |
|
-2.25% | -19.93% |
| 01/10 | Taconic Biosciences, Inc. And genOway Partner To Expand U.S. Access To Advanced Humanized Mouse Models | CI |
| 23/09 | GenOway teams up with Taconic Biosciences to accelerate in the United States |
Company Valuation: genOway
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 21.45 | 37.85 | 35.3 | 40.59 | 34.58 | 24.99 |
| Change | - | 76.49% | -6.76% | 15% | -14.82% | -27.73% |
| Enterprise Value (EV) 1 | 29.49 | 43.07 | 39.45 | 43.56 | 35.2 | 31.7 |
| Change | - | 46.05% | -8.41% | 10.42% | -19.2% | -9.93% |
| P/E | - | - | - | - | - | - |
| PBR | - | - | - | - | - | - |
| PEG | - | - | - | - | - | - |
| Capitalization / Revenue | 1.32x | 1.93x | 1.67x | 1.62x | 1.34x | 0.96x |
| EV / Revenue | 1.81x | 2.2x | 1.87x | 1.74x | 1.36x | 1.22x |
| EV / EBITDA | 34.9x | 99.8x | 13.1x | 7.49x | 9.04x | 7.16x |
| EV / EBIT | -78.2x | -54.6x | 80.7x | 27.8x | 27x | 24.9x |
| EV / FCF | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | - | - | - | - | - | - |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 16.29 | 19.59 | 21.09 | 25.02 | 25.84 | 26.03 |
| EBITDA 1 | 0.844 | 0.4318 | 3.006 | 5.815 | 3.894 | 4.428 |
| EBIT 1 | -0.3771 | -0.7893 | 0.4886 | 1.565 | 1.304 | 1.274 |
| Net income 1 | -0.6873 | -0.3226 | 0.7778 | 1.568 | 1.831 | 0.9278 |
| Net Debt 1 | 8.045 | 5.22 | 4.156 | 2.973 | 0.623 | 6.718 |
| Reference price 2 | 3.100 | 4.290 | 4.000 | 4.600 | 3.750 | 2.710 |
| Nbr of stocks (in thousands) | 6,919 | 8,824 | 8,824 | 8,824 | 9,220 | 9,220 |
| Announcement Date | 28/04/22 | 28/04/22 | 28/04/23 | 01/05/24 | 29/04/25 | 30/04/26 |
1EUR in Million2EUR
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| - | - | - | - | 2.23Cr | ||
| 18.77x | 6.69x | 13.41x | 1.58% | 6.5TCr | ||
| 35.3x | 6.27x | 18.74x | 0.92% | 5.12TCr | ||
| 27.56x | 7.53x | 23.83x | 0.05% | 5.12TCr | ||
| 34.01x | 3.32x | 14.33x | -.--% | 4.39TCr | ||
| 48.9x | 5.59x | 30.73x | -.--% | 4.2TCr | ||
| -18.47x | 189.62x | -19.51x | -.--% | 3.81TCr | ||
| 28.97x | 8.21x | 21.25x | 0.37% | 3.32TCr | ||
| 29.19x | 6.17x | 16.01x | -.--% | 2.52TCr | ||
| 30.74x | 5.69x | 19.09x | -.--% | 2.25TCr | ||
| Average | 26.11x | 26.57x | 15.32x | 0.32% | 3.72TCr | |
| Weighted average by Cap. | 25.97x | 25.01x | 15.48x | 0.44% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- ALGEN Stock
- Valuation genOway
Select your edition
All financial news and data tailored to specific country editions
















